Document Detail


Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.
MedLine Citation:
PMID:  23289909     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: The ATP-binding cassette transporter ABCG2 can actively extrude a broad range of endogenous and exogenous substrates across biological membranes. Thereby, ABCG2 limits oral drug bioavailability, mediates hepatobiliary and renal excretion and participates functionally in the blood-brain barrier.
AREAS COVERED: The paper provides a review of the clinical evidence of the role of ABCG2 in the bioavailability and brain disposition of drugs. It also sheds light on the value of experimental/preclinical data in predicting the role of ABCG2 in pharmacokinetics in humans.
EXPERT OPINION: Experimental studies indicate that ABCG2 may limit the oral bioavailability and brain penetration of many drugs. ABCG2 has also been recognized as an important determinant of the disposition of some drugs in humans. For example, loss-of-function variants of ABCG2 affect the pharmacokinetics and pharmacodynamics of rosuvastatin in a clinically significant manner. Moreover, clinically relevant pharmacokinetic drug-drug interactions have been attributed to ABCG2 inhibition. However, examples from human studies are still rare compared with the overwhelming evidence from experimental studies. The large degree of functional redundancy of ABCG2 with other transporters such as P-glycoprotein may explain the rare occurrence of ABCG2-dependent drug-drug interactions in humans. Providing clinicians with consolidated information on the clinically relevant interactions of drugs with ABCG2 remains a matter of future exploration.
Authors:
Rebecca Schnepf; Oliver Zolk
Related Documents :
24440669 - Synthesis and characterization of curcumin loaded polymer/lipid based nanoparticles and...
8139919 - Infrared linear dichroism studies of dna-drug complexes: quantitative determination of ...
23466549 - Epirubicin loaded to pre-polymerized poly(butyl cyanoacrylate) nanoparticles: preparati...
22952939 - Activity of trifluoperazine against replicating, non-replicating and drug resistant m. ...
23228469 - From a cytotoxic agent to the discovery of a novel antimalarial agent.
24374609 - Development of salvianolic acid b- tanshinone ii a- glycyrrhetinic acid compound liposo...
20062859 - Real-time monitoring of drug release.
12429469 - Potential applications of plga film-implants in modulating in vitro drugs release.
21811439 - The striatal balancing act in drug addiction: distinct roles of direct and indirect pat...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-07
Journal Detail:
Title:  Expert opinion on drug metabolism & toxicology     Volume:  9     ISSN:  1744-7607     ISO Abbreviation:  Expert Opin Drug Metab Toxicol     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-19     Completed Date:  2013-08-15     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101228422     Medline TA:  Expert Opin Drug Metab Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  287-306     Citation Subset:  IM    
Affiliation:
Friedrich-Alexander Universität Erlangen-Nürnberg, Institute of Experimental and Clinical Pharmacology and Toxicology, Fahrstr. 17, 91054 Erlangen, Germany. oliver.zolk@pharmakologie.med.uni-erlangen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
ATP-Binding Cassette Transporters / metabolism*
Absorption
Administration, Oral
Animals
Biological Availability
Biological Transport
Brain / drug effects,  metabolism
Drug Interactions
Fluorobenzenes / administration & dosage,  pharmacokinetics*
Humans
Neoplasm Proteins / metabolism*
P-Glycoprotein / metabolism
Pyrimidines / administration & dosage,  pharmacokinetics*
Sulfonamides / administration & dosage,  pharmacokinetics*
Tissue Distribution
Chemical
Reg. No./Substance:
0/ABCG2 protein, human; 0/Fluorobenzenes; 0/Neoplasm Proteins; 0/P-Glycoprotein; 0/Pyrimidines; 0/Sulfonamides; 287714-41-4/rosuvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Telehealth and Indian Healthcare: Moving to Scale and Sustainability.
Next Document:  Treatment of Breast and Lung Cancer Cells with a N-7 Benzyl Guanosine Monophosphate Tryptamine Phosp...